The Edit Review: $259/mo, and the $200 Catch

The Edit (theedithealth.com) advertises semaglutide at $200 and tirzepatide at $300. Neither number is what you will pay in month two. Both are a first month only, printed larger than the standing rates they discount, and those rates are $259 and $349. We first checked the whole ladder in August 2026 and re-read it on 1 September; both standing prices had risen, by $50 and $40. What did not change is the part that makes this program unusual: the arithmetic on every prepay rung still survives being checked. Apart from the headline, the pricing is honest. It is also, here, expensive.

The real ladder

Month to month, semaglutide is $259 and tirzepatide is $349. Prepay and the per-month figure drops: $575 once for three months of semaglutide, $1,065 once for six; $855 once for three months of tirzepatide, $1,575 once for six.¹ Those four totals are exactly what they were in August, which is worth saying plainly — the price rise landed entirely on the month-to-month rate.

Those prepay rungs are labeled "billed once at the start of the plan", which is the labeling most operators skip, and the per-month figures the site prints beside them divide correctly — $575 over three months is $192, $1,065 over six is $178, $855 over three is $285, $1,575 over six is $263. We check that division on every provider because it is where the padding usually hides. Here there is none.

What six months actually costs

Take semaglutide. Paying month to month, six months is $1,554. Buying the six-month plan up front is $1,065 — a difference of $489, and you are committed. Tirzepatide runs $2,094 month to month against $1,575 prepaid, a difference of $519. In August those same gaps were $189 and $279, so the case for committing has roughly doubled without the commitment getting any cheaper.

That is now a large discount for a real commitment, which cuts both ways: it is worth more if you are certain you will stay on treatment, and it costs more to be wrong. The teaser-rate playbook is worth reading against this page specifically: the first-month headline does exactly what a teaser does — it wins the click at a number that appears once — but the rest of the structure does none of the things a teaser structure does. There is no step-up, no minimum term, and no hidden month-two rate. The recurring price is printed on the same page as the promo, struck through beneath it. What the promo does not carry is an end date, a code, or any statement of whether it applies to the prepay plans at all.

Where it lands on price

$259 a month for compounded semaglutide is upper-quartile, and the September rise moved it further up. We are a savings desk and we are not going to pretend otherwise: many programs on the semaglutide price ladder beat it outright, and two we re-read the same day — Pepti at $109 every 28 days and Trellis Vitality at $150 month to month — undercut it by $109 to $150 a month with published ladders of their own. Over six months that is a $654 to $900 gap. The Edit's case is not price. It is that almost everything it publishes about price turns out to be true.

Who is actually behind it

The medical group is Arora Health & Aesthetics, LLC, medical director Dr. Sean Arora, NPI 1841729449 — active in the federal NPPES registry, Family Medicine, licensed in New Hampshire, Michigan and Washington.² The dispensing pharmacy is named: The Pharmacy Hub, inside what the site calls The Edit Health Pharmacy Network. A named pharmacy plus a verifiable prescriber NPI puts this provider ahead of most of the market, and well ahead of the three programs in this batch that name neither. If you are not sure why that matters, how to verify a compounding pharmacy is legitimate is the checklist.

One thing to hold onto: Trellis Vitality uses the same medical group and the same medical director. Different pharmacies, different prices, separable products — but they are not two independent clinical opinions. If you are shortlisting both as alternatives to each other, you are shortlisting one clinical operation twice.

The corporate entity is The Edit Health LLC, a Texas management services organization at 5900 Balcones Drive, Austin. It also operates a second domain, startyouredit.com.

The rest of the shelf, and the parts that are free

Beyond the two GLP-1 protocols: NAD+ at $249 a month, re-confirmed on 1 September, alongside a hormone line starting at $49 for oral progesterone, $69 for estradiol and $139 for a compounded topical.¹ The site states plainly that it does not sell research-use-only compounds, and the catalog backs that up — no retatrutide, no oral GLP-1, no nasal line.

Starting is genuinely free: no charge and no card on file to begin. Once a visit has occurred the visit fee is non-refundable, but no visit fee is charged up front and none is priced for a weight-loss patient anywhere. Prescriptions are final sale, which is standard for compounded medication. Membership cancels at the end of the current period with no proration. One caveat found on the September read and worth carrying: the published cancellation and refund policies say they do not govern — where they differ from a membership agreement held behind the account gate, that agreement controls, and nothing on the public site is that agreement. The site claims all 50 states and hedges the claim in the same paragraph; no state list is published anywhere on it.

The regulatory screen

We ran the trading name, the legal entity, the medical group and the named pharmacy against the FDA's live warning-letter index in August 2026 and again on 1 September. Zero company-column matches on all four, both times.³ Each pass carried a positive control — an unrelated seller with a real letter — which returned correctly, so the zeros are evidence rather than a query that failed quietly.

The verdict for a bargain hunter

Ignore the $200. Budget $259 a month, or $1,065 for six months if you are sure. What you are buying at that price is a named pharmacy, a checkable prescriber, and arithmetic that survives being checked. What you are not buying is a low price, and it got less low in September. If price is the binding constraint, start from how to choose a GLP-1 provider without overpaying and work down the ladder; if verification is the binding constraint, this is one of the few programs we have read that clears it. The rest of what we publish sits in the research library.